GlassScriptPhysician profile
Jennifer M Rullan
NPI 1447484811
$13,846.08
in general payments reported to CMS, 2019-2025
35 companies · $3,324 in 2025
The $3,324 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $369 · 2021: $863 · 2022: $1,995 · 2023: $2,496 · 2024: $3,124 · 2025: $3,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,583 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,583.48 |
| Education | $361.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.87 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Janssen Biotech, INC. | $1,299.13 | 2021-2025 | Tremfya |
| Genzyme Corporation | $1,126.52 | 2019-2025 | |
| Pfizer INC. | $936.19 | 2019-2025 | |
| Allergan, INC. | $831.82 | 2019-2022 | |
| Incyte Corporation | $713.85 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $687.68 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $629.84 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Arcutis Biotherapeutics, INC. | $579.57 | 2023-2025 | Zoryve |
| Merz North America, INC. | $579.33 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $548.40 | 2019-2025 | Ilumya |
| Ucb, INC. | $434.47 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $403.19 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $395.46 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $357.12 | 2022-2025 | Dupixent, Libtayo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $351.79 | 2019-2023 | Jublia, Arazlo |
| Lilly USA, LLC | $307.01 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $294.02 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $191.49 | 2019-2025 | |
| Almirall LLC | $184.01 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $167.05 | 2020-2022 | |
| Biofrontera INC. | $134.75 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Eli Lilly and Company | $99.00 | 2025 | |
| Hill Dermaceuticals, INC. | $97.84 | 2025 | Tolak |
| Mimedx Group, INC. | $94.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.32 | 2024-2025 | Spevigo |
| Botanix Sb INC | $38.97 | 2025 | Sofdra |
| Organon LLC | $38.96 | 2025 | Vtama |
| Genentech USA, INC. | $34.84 | 2021-2024 | Xolair |
| Revance Therapeutics, INC. | $32.26 | 2024 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $17.39 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.73 | 2019 | |
| Mission Pharmacal Company | $14.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Sensus Healthcare, INC. | $10.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Rullan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.